Oncology

Roche's takes a step- forward to treat Huntington's disease A new drug co-developed by Roche and Ionis Pharmaceuticals can be a potential candidate to treat Huntington's disease. RG6042 which is an antisense oligonucleotide is able to successfully lower down the production of a toxic protein that results in dysfunction of neurons. The successful Phase 1/2a trials have boosted the hopes of Roche to take the drug directly in Phase III trials. Pfizer's Tafamidis back in the Market Once rejected by the U.S. FDA, Pfizer's tafamidis recently was able to win the FDA nod to treat transthyretin amyloid cardiomyopathy, a rare and fatal heart disease. The oral drug wil...